Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | SI | P14410 | 1/20 | 0.52 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 5/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | CASP1 | P29466 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11056301 | 0.89 | TSHR (0.53) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL30888816 | 0.87 | TSHR (0.50) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL17853913 | 0.82 | CES2 (0.40) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL1006516 | 0.81 | — | — | |
| SCHEMBL19730844 | 0.80 | CYP2D6 (0.60) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL8892963 | 0.80 | TSHR (0.43) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL9589394 | 0.79 | TSHR (0.50) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL10918181 | 0.79 | MGAM (0.46) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL9517329 | 0.79 | TSHR (0.48) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL10788950 | 0.79 | TSHR (0.48) | MGAMGAASIMGAM2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4713320-A2 | BCAT2 INHIBITORS | Agios Pharmaceuticals, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| WO-2024238820-A2 | BCAT2 INHIBITORS | AGIOS PHARMACEUTICALS, INC. (US) | 2024-11-21 | — | — | WO | disclosed |
| EP-4430036-A2 | BCAT2 INHIBITORS | Agios Pharmaceuticals, Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| WO-2023086539-A2 | BCAT2 INHIBITORS | AGIOS PHARMACEUTICALS, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| EP-3454657-B1 | DIHYDROISOXAZOLE COMPOUND FOR USE IN CONTROLLING SEA LICE | ELANCO TIERGESUNDHEIT AG (CH) | 2020-05-13 | — | — | EP | disclosed |
| US-10537549-B2 | Dihydroisoxazole compound for use in controlling sea lice | ELANCO TIERGESUNDHEIT AG (CH) | 2020-01-21 | — | — | US | disclosed |
| US-10537549-B2 | Dihydroisoxazole compound for use in controlling sea lice | ELANCO TIERGESUNDHEIT AG (CH) | 2020-01-21 | — | — | US | disclosed |
| US-20190142795-A1 | DIHYDROISOXAZOLE COMPOUND FOR USE IN CONTROLLING SEA LICE | INTERVET INC. | 2019-05-16 | — | — | US | disclosed |
| US-20190142795-A1 | DIHYDROISOXAZOLE COMPOUND FOR USE IN CONTROLLING SEA LICE | INTERVET INC. | 2019-05-16 | — | — | US | disclosed |
| EP-3454657-A1 | DIHYDROISOXAZOLE COMPOUND FOR USE IN CONTROLLING SEA LICE | Elanco Tiergesundheit AG (CH) | 2019-03-20 | — | — | EP | disclosed |
| WO-2012155352-A1 | DIHYDROISOXAZOLE COMPOUNDS, PARASITICIDAL USES AND FORMULATIONS THEREOF | ELI LILLY AND COMPANY (US) | 2012-11-22 | — | — | WO | disclosed |
| WO-2012155352-A1 | DIHYDROISOXAZOLE COMPOUNDS, PARASITICIDAL USES AND FORMULATIONS THEREOF | ELI LILLY AND COMPANY (US) | 2012-11-22 | — | — | WO | disclosed |
| WO-2012155676-A1 | PARASITICIDAL COMPOUNDS, METHODS, AND FORMULATIONS | ELI LILLY AND COMPANY (US) | 2012-11-22 | — | — | WO | disclosed |
| WO-2012155676-A1 | PARASITICIDAL COMPOUNDS, METHODS, AND FORMULATIONS | ELI LILLY AND COMPANY (US) | 2012-11-22 | — | — | WO | disclosed |
| WO-2012158396-A1 | PARASITICIDAL DIHYDROISOXAZOLE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2012-11-22 | — | — | WO | disclosed |
| US-20120196902-A1 | SULFOXIMINES AS KINASE INHIBITORS | ALLERGAN, INC. | 2012-08-02 | — | — | US | disclosed |
| US-20120108618-A1 | THIA-TRIAZA-INDACENES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-03 | — | — | US | disclosed |
| US-20120108618-A1 | THIA-TRIAZA-INDACENES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-03 | — | — | US | disclosed |
| US-20120108618-A1 | THIA-TRIAZA-INDACENES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-03 | — | — | US | disclosed |
| WO-2010122091-A1 | THIA-TRIAZA-AS-INDACENES AS PI3-KINASES INHIBITORS FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120196902-A1 | SULFOXIMINES AS KINASE INHIBITORS | SRC, PTK2B, TYRO3 | MGAM 2310/4885GAA 3138/4885SI 4246/4885 |
| US-10537549-B2 | Dihydroisoxazole compound for use in controlling sea lice | SQLE, SLC9A5, RDX | MGAM 1817/4885GAA 1021/4885SI 448/4885 |
| US-20120108618-A1 | THIA-TRIAZA-INDACENES | CCNA1, MKI67, CCNT1 | MGAM 4398/4885GAA 980/4885SI 3196/4885 |
| US-20190142795-A1 | DIHYDROISOXAZOLE COMPOUND FOR USE IN CONTROLLING SEA LICE | SQLE, SLC9A5, RDX | MGAM 1817/4885GAA 1021/4885SI 448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.